Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
86.6M
-
Number of holders
-
173
-
Total 13F shares, excl. options
-
71M
-
Shares change
-
+168K
-
Total reported value, excl. options
-
$1.03B
-
Value change
-
-$1.57M
-
Put/Call ratio
-
0.74
-
Number of buys
-
91
-
Number of sells
-
-70
-
Price
-
$14.52
Significant Holders of Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) as of Q3 2023
209 filings reported holding SNDX - Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share as of Q3 2023.
Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) has 173 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 71M shares
of 86.6M outstanding shares and own 82% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (7.64M shares), BlackRock Inc. (5.88M shares), VANGUARD GROUP INC (3.62M shares), STATE STREET CORP (3.6M shares), Kynam Capital Management, LP (3.6M shares), Avidity Partners Management LP (2.82M shares), PFM Health Sciences, LP (2.72M shares), Eversept Partners, LP (2.6M shares), Avoro Capital Advisors LLC (2.56M shares), and Paradigm Biocapital Advisors LP (2.39M shares).
This table shows the top 173 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.